Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment

摘要

Continuous androgen deprivation therapy (ADT) is the mainstay of treatment for metastatic prostate cancer. Both injectable luteinizing hormone–releasing hormone (LHRH) agonists and antagonists (here LHRH interchangeable to gonadotropin-releasing hormone, GnRH) are the current standard of care for ADT in prostate cancer. The novel oral form of effective GnRH antagonist is a very promising alternative to the current landscape of ADT.